CDx Clinical Validation Strategy: Enrichment Designs, Cutoffs, and Bridging Studies in 2023 CDx Clinical Validation Strategy: Enrichment Designs, Cutoffs, and Bridging Studies in 2023 This comprehensive guide outlines the regulatory framework and strategic considerations necessary for clinical validation of Companion Diagnostics (CDx). It emphasizes enrichment designs, establishing cutoffs, and conducting bridging studies, targeted at professionals involved in regulatory affairs, quality assurance, and clinical operations in the US. 1. Understanding the Companion Diagnostic Regulatory Landscape The first step in establishing a clinical validation strategy for a companion diagnostic (CDx) is to have a clear understanding of the regulatory landscape. In the…

Drug–CDx Labeling Alignment: Intended Use and Companion Claim Risk Controls in 2023 Drug–CDx Labeling Alignment: Intended Use and Companion Claim Risk Controls in 2023 The intersection of drug development and diagnostics has necessitated comprehensive regulatory frameworks to ensure that both the drug and its accompanying companion diagnostics (CDx) align seamlessly. This article serves as a step-by-step tutorial guide aimed at professionals involved in drug–CDx co-development, with a particular focus on the regulatory pathways, documentation expectations, and necessary compliance measures in the United States. By following this guide, regulatory affairs, quality assurance, and clinical teams will position themselves to navigate the…

Companion Diagnostic Master File (CDMF) Strategy: When It Helps US Submissions in 2023 Companion Diagnostic Master File (CDMF) Strategy: When It Helps US Submissions in 2023 In the evolving landscape of personalized medicine, the regulatory pathway for companion diagnostics (CDx) has become increasingly complex. With the introduction of the Companion Diagnostic Master File (CDMF), stakeholders must understand its strategic role in facilitating successful submissions to the FDA and other regulatory bodies. This article provides a comprehensive step-by-step tutorial on leveraging the CDMF strategy to enhance US submissions. Whether you are involved in regulatory affairs, quality assurance, or clinical research, this…

Global CDx Filing Strategy Anchored on US Approval in 2023: EU IVDR and Japan PMDA Alignment Global CDx Filing Strategy Anchored on US Approval in 2023: EU IVDR and Japan PMDA Alignment The development and approval of companion diagnostics (CDx) are critical to the advancement of personalized medicine. This article provides a comprehensive guide for pharmaceutical and clinical research professionals on navigating the complex landscape of regulatory requirements for companion diagnostics, specifically focusing on strategies for aligning US, EU, and Japanese regulations. This guide is particularly useful for those involved in companion diagnostic regulatory consulting, addressing the steps necessary to…